Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 in Chinese Overweight or Obese Participants
NCT07121153Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of amycretin in obesity, sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events at Day 23. Started Aug 2025; status: completed.
02
Drugs
amycretin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07121153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121153.